BioMerieux (CHIX:BIMP) Long-Term Debt : €0 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Long-Term Debt?

BioMerieux's Long-Term Debt for the quarter that ended in Dec. 2024 was €0 Mil.

BioMerieux's quarterly Long-Term Debt increased from Dec. 2023 (€234 Mil) to Jun. 2024 (€237 Mil) but then declined from Jun. 2024 (€237 Mil) to Dec. 2024 (€0 Mil).

BioMerieux's annual Long-Term Debt increased from Dec. 2022 (€225 Mil) to Dec. 2023 (€234 Mil) but then declined from Dec. 2023 (€234 Mil) to Dec. 2024 (€0 Mil).

BioMerieux Long-Term Debt Historical Data

The historical data trend for BioMerieux's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Long-Term Debt Chart

BioMerieux Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

249.20

265.20

224.80

234.10

BioMerieux Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															224.80	231.90	234.10	237.20	-

BioMerieux (CHIX:BIMp) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioMerieux Long-Term Debt Related Terms

Thank you for viewing the detailed overview of BioMerieux's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (CHIX:BIMp) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BMXMF:USA 0RUG:UK BIM:France EYWN:Germany

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

BioMerieux Headlines

No Headlines